SCHEMBL24253339

SCHEMBL24253339

CC(C)Cc1cc(F)cc2c1CCN(C)C2

nearest known ligand 0.37

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MAOA P21397 4/20 0.37
MAOB P27338 4/20 0.37
SLC6A4 P31645 1/20 0.37
HSP90AA1 P07900 2/20 0.35
HSP90AB1 P08238 1/20 0.35
CYP2C19 P33261 1/20 0.34
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34
KLKB1 P03952 1/20 0.32
NMT1 P30419 1/20 0.32
HTR6 P50406 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24688335 0.82 HSP90AA1 (0.35) MAOAMAOBSLC6A4HSP90AA1HSP90AB1
SCHEMBL24253475 0.77 HTR2C (0.42) MAOAMAOBHSP90AA1HSP90AB1HTR2C
SCHEMBL25444509 0.76 MAOA (0.49) MAOAMAOBCYP2C19HTR2CHTR2B
SCHEMBL24253500 0.75 MAOA (0.45) MAOAMAOBSLC6A4HSP90AA1CYP2C19
SCHEMBL25091105 0.72 HTR2C (0.40) MAOAMAOBHSP90AA1HSP90AB1HTR2C
SCHEMBL24253534 0.71 HTR2C (0.42) MAOAMAOBHTR2CHTR2B
SCHEMBL24253563 0.68 MAOA (0.35) MAOAMAOBSLC6A4HTR6
SCHEMBL25121974 0.67 ALDH1A1 (0.37) MAOAMAOBHSP90AA1HSP90AB1HTR2C
SCHEMBL22993218 0.66 MAOA (0.47) MAOAMAOBSLC6A4NMT1
SCHEMBL2625799 0.65 MAOA (0.55) MAOAMAOBSLC6A4HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-11613527-B2 Enzyme inhibitors KALVISTA PHARMACEUTICALS LIMITED (GB) 2023-03-28 US disclosed
US-20220048894-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250080-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 MAOA 175/4885MAOB 71/4885SLC6A4 4581/4885
US-11613527-B2 Enzyme inhibitors SERPINB1, KLKB1, SERPINE1 MAOA 175/4885MAOB 71/4885SLC6A4 4581/4885
US-20220048894-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 MAOA 175/4885MAOB 71/4885SLC6A4 4581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.